Tolerability of the COX-1/COX-2 inhibitor lornoxicam in the treatment of acute and rheumatic pain

摘要

Aim: To assess the safety of lornoxicam with particular focus on gastrointestinal (Gl) events. Methods: Data on adverse drug reactions (ADRs) were pooled from 60 comparative studies of lornoxicam. Results: A total of 6420 patients received lornoxicam, 1192 received placebo and 3770 received a comparator analgesic. ADRs were reported by 21 of lornoxicam-treated patients, with Gl events the most frequent (14 vs 8 with placebo). Across 15 studies that compared lornoxicam (n = 1287) with another NSAID (n = 1010), there was a reduced risk of a Gl ADR with lornoxicam (0.78 95 Cl: 0.64-0.96; p = 0.017). Conclusion: Lornoxicam was well tolerated with the type of Gl events observed consistent with the known safety profile of NSAIDs.